The short version of BPC-157 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes. The most common side effects include nausea, vomiting, headache, diarrhea, and injection site pain. Dasiglucagon was approved for medical use in the United States in March 2021.
=== Medicine === Surfactants act to cause the displacement of air from the matrix of cotton pads and bandages so that medicinal solutions can be absorbed for application to various body areas. They also act to displace dirt and debris by the use of detergents in the washing of wounds and via the application of medicinal lotions and sprays to surface of skin and mucous membranes. Surfactants enhance remediation via soil washing, bioremediation, and phytoremediation. Many spermicides contain surfactants (such as nonoxynol-9).
== Statement == Let P be an arbitrary point inside the triangle ABC. From P and ABC, define U, V, and W as the points where the angle bisectors of BPC, CPA, and APB intersect the sides BC, CA, AB, respectively. Then Barrow's inequality states that
Minerva is an episodic series of single-player modifications ("mods") for Valve's Half-Life 2. The mod was created by Adam Foster. The plot and settings of Minerva are linked to Someplace Else, Foster's original map for Half-Life, and to Half-Life 2. The mod was released on Steam on April 30, 2013.
Sources: en.wikipedia.org
=== "Merck" name legal dispute === In 191 of 193 countries, the original Merck company, the Merck Group of Darmstadt, owns the rights to the "Merck" name. In the United States and Canada, the company trades under the name EMD (an abbreviation of Emanuel Merck, Darmstadt), its legal name here says Merck KGaA, Darmstadt, Germany, and instead of "Merck Group", the "EMD Group" name is used. In the United States and Canada, Merck & Co. holds the rights to the trademark "Merck", while in the rest of the world the company trades under the name MSD (an abbreviation of Merck, Sharp & Dohme) and its legal name says here Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc. Kenilworth, NJ, USA. In 2015 the Merck Group adopted a new logo and said it will be "much more aggressive" about protecting the brand of "the real Merck". Merck of Darmstadt has initiated litigation against its former subsidiary, Merck & Co. (MSD) of Kenilworth, in several countries over infringing use of the Merck name. In 2016, the High Court of Justice in the United Kingdom ruled that MSD had breached an agreement with its former parent company and that only Merck of Darmstadt is entitled to use the Merck name in the United Kingdom. The judge also held that MSD's use of "Merck" as part of branding on its global websites were directed to the UK and infringed Merck's trade mark rights in the UK.
== Blood doping == Blood doping is the injection of red blood cells, related blood products that contain red blood cells, or artificial oxygen containers. This is done by extracting and storing one's own blood prior to an athletic competition, well in advance of the competition so that the body can replenish its natural levels of red blood cells, and subsequently injecting the stored blood immediately before competition. The resulting unnatural level of red blood cells improves oxygen transport and athletic endurance; thus, it is prohibited in most events. It is often used in extreme sports like cycling, snowboarding, and skiing where endurance is highly valued. The most famous example of this type of doping is Lance Armstrong's performance in the Tour de France.
atlas evolved from the fusion of a protein-coding gene that arose at the base of Drosophila genus and a conserved non-coding RNA. Comparative analysis of the transcriptomes of testis and accessory glands, a somatic tissue of males that is important for fertility, of D. melanogaster suggests that de novo genes make greater contribution to the transcriptomic complexity of testis as compared to accessory glands. Single-cell RNA-seq of D. melanogaster testis revealed that the expression pattern of de novo genes was biased toward early spermatogenesis. In humans, a study that identified 60 human-specific de novo genes found that their average expression, as measured by RNA-seq, was highest in the testes. Another study looking at mammalian-specific genes more generally also found enriched expression in the testes. Transcription in mammalian testes is thought to be particularly promiscuous, due in part to elevated expression of the transcription machinery and an open chromatin environment. Along with the immune-privileged nature of the testes, this promiscuous transcription is thought to create the ideal conditions for the expression of non-genic sequences required for de novo gene birth. Testes-specific expression seems to be a general feature of all novel genes, as an analysis of Drosophila and vertebrate species found that young genes showed testes-biased expression regardless of their mechanism of origination.
Sources: en.wikipedia.org
=== Mesoamerica === Lightweight concrete was designed and used for the construction of structural elements by the pre-Columbian builders who lived in a very advanced civilisation in El Tajin near Mexico City, in Mexico. A detailed study of the composition of the aggregate and binder show that the aggregate was pumice and the binder was a pozzolanic cement made with volcanic ash and lime.
Jonna, angry, leads Clara to place her ear onto the small hole in the pool cover and stabs her in the ear with a shard of tile. In retaliation, Clara turns on the automatic pool cleaning system, causing the girls to begin suffocating in chlorine, but she turns it off again when she realises the possible consequences and leaves. Bree reveals to Jonna that during the accident that killed their father, she purposely prevented their father from escaping, calling him a monster as he had been sexually abusing the girls during their adolescence. Meanwhile, Clara returns, having realized the error of her ways. She tries to open the pool cover but her passcode no longer works. She tells the sisters they are on their own and leaves again. Bree grows weak. Jonna succeeds in ripping the metal grill off the bottom of the pool, something Bree had previously tried and failed to do. She smashes the pool cover and they escape. Jonna gives Bree her insulin shot. Clara returns with a gun, threatening to kill the sisters as she does not want to go to prison again. However, she feels sympathetic, puts the gun down, and returns their belongings. Jonna calls the police and Clara awaits her fate, but Jonna tells her to leave and the two exchange smiles. Paramedics arrive and Jonna returns Bree's engagement ring, which Clara had taken. When Bree asks how she got it back, Jonna replies, "We killed the monster", echoing what Bree said about killing their father, and implying that the monster that was inside Clara died when Jonna showed her sympathy and forgiveness.
12 November – Downing Street confirms that Sue Gray will not take up a role as the prime minister's envoy to the nations and regions. The government sends a contingency of 470 delegates to the COP29 climate summit in Azerbaijan, with an estimated carbon dioxide footprint of at least 338 tons. The delegation is reported to comprise 354 government officials or ministers and 116 others including representatives from British overseas territories and crown dependencies, journalists, business figures and policy experts. By comparison, Italy sends 437, the US 405 and France 115. Starmer tells the COP29 climate conference that the UK will aim to reduce its emissions by 8% by 2035. Stephen Flynn, the SNP's leader at Westminster, announces his intention to stand at the 2026 Scottish Parliament election. Former Welsh government legal advisor Mick Antoniw and ex-minister Julie Morgan tell BBC News that subject to being passed at Westminster, the Terminally Ill Adults (End of Life) Bill would require a vote in the Senedd to become legal in Wales. 13 November – Health Secretary Wes Streeting orders a review into the potential cost to the NHS of implementing changes to the law regarding assisted dying. A report published by the Electoral Commission reveals that over half the 2024 general election candidates faced some kind of abuse. 14 November – Chancellor Rachel Reeves is reported to be planning the "biggest pension reform in decades" by merging council pension schemes into "pension megafunds" hoping they will boost economic growth.
Oganesson is a synthetic chemical element; it has symbol Og and atomic number 118. It was first synthesized in 2002 at the Joint Institute for Nuclear Research (JINR) in Dubna, near Moscow, Russia, by a joint team of Russian and American scientists. In December 2015, it was recognized as one of four new elements by the Joint Working Party of the international scientific bodies IUPAC and IUPAP. It was formally named on 28 November 2016. The name honors the nuclear physicist Yuri Oganessian, who played a leading role in the discovery of the heaviest elements in the periodic table. Oganesson has the highest atomic number and highest atomic mass of all known elements. On the periodic table of the elements it is a p-block element, a member of group 18, and the last member of period 7. Its only known isotope, oganesson-294, is highly radioactive, with a half-life of 0.7 ms. This half-life is too short for chemical studies. Because of relativistic effects, theoretical studies predict that it would be a solid at room temperature, and significantly reactive, unlike the other members of group 18 (the noble gases).
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.